A Phase I Study of CS5007 in Participants With Advanced Solid Tumors

Summary

This is a first-in-human (FIH), open-label, and multi-center Phase I study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5007 as monotherapy in participants with advanced solid tumors. The study is comprised of a Phase Ia dose escalation and Phase Ib dose expansion.

Timeline

Start

2026-06

Primary completion

2028-01

Completion

2029-01

Drugs

Indications